NASDAQ:FSTX • US30315R1077
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for F-STAR THERAPEUTICS INC (FSTX).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2022-07-15 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2022-06-24 | SVB Leerink | Downgrade | Outperform -> Market Perform |
| 2022-05-11 | SVB Leerink | Maintains | Outperform |
| 2021-08-17 | SVB Leerink | Maintains | Outperform |
| 2021-07-08 | SVB Leerink | Initiate | Outperform |
| 2021-06-09 | B. Riley Securities | Initiate | Buy |
| 2021-05-18 | HC Wainwright & Co. | Initiate | Buy |
| 2021-04-16 | Oppenheimer | Initiate | Outperform |
| 2021-04-08 | William Blair | Initiate | Outperform |
| 2021-03-24 | Laidlaw & Co. | Initiate | Buy |
| 2021-03-01 | HC Wainwright & Co. | Initiate | Buy |
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 11.26M | 21.167M 87.98% | 4.093M -80.66% | 1.275M -68.85% | 3.4M 166.67% | 2.733M -19.62% | 24.78M 806.70% | 47.121M 90.16% | 128.32M 172.32% | 314.52M 145.11% | 576.39M 83.26% | ||
| EBITDA YoY % growth | -32.66M -15.90% | -21.25M 34.94% | -30.072M -41.52% | -53.754M -78.75% | -62.322M -15.94% | -75.582M -21.28% | -84.15M -11.34% | -78.132M 7.15% | -68.646M 12.14% | N/A | N/A | N/A | |
| EBIT YoY % growth | -33.02M -15.98% | -22.39M 32.19% | -30.714M -37.18% | -56.986M -85.54% | -68.43M -20.08% | -79.069M -15.55% | -87.95M -11.23% | -80.542M 8.42% | -66.819M 17.04% | 41.086M 161.49% | 159.58M 288.40% | 382.26M 139.54% | |
| Operating Margin | N/A | -198.85% | -145.10% | -1,392.29% | -5,367.06% | -2,325.56% | -3,218.07% | -325.03% | -141.80% | 32.02% | 50.74% | 66.32% | |
| EPS YoY % growth | -5.88 7.55% | -6.54 -11.22% | -2.01 69.27% | -2.81 -39.55% | -3.05 -8.82% | -2.81 7.99% | -2.49 11.20% | -1.38 44.79% | -1.43 -3.70% | 1.11 177.86% | 4.27 284.40% | 10.18 138.19% |
All data in USD
| Q4 / 22 | Q1 / 23 | Q2 / 23 | Q3 / 23 | Q4 / 23 | Q1 / 24 | Q2 / 24 | Q3 / 24 | Q4 / 24 | |
|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.56 -217.41% | -0.78 -36.00% | -0.80 9.59% | -0.71 15.00% | -0.73 -30.32% | -0.78 | -0.87 -8.97% | -0.91 -27.14% | -0.95 -29.17% |
| Revenue Q2Q % growth | -100.00% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -15.09M -449.06% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
All data in USD
9 analysts have analysed FSTX and the average price target is 7.14 USD. This implies a price increase of 0.28% is expected in the next year compared to the current price of 7.12.
F-STAR THERAPEUTICS INC (FSTX) will report earnings on 2023-05-08.
The consensus EPS estimate for the next earnings of F-STAR THERAPEUTICS INC (FSTX) is -0.56 USD and the consensus revenue estimate is 0 USD.
The consensus rating for F-STAR THERAPEUTICS INC (FSTX) is 48.8889 / 100 . This indicates that analysts generally have a neutral outlook on the stock.